EphA3 ADC

EphA3 ADC is a research-stage antibody-drug conjugate (ADC) designed to target the Eph type-A receptor 3 (EphA3), a protein frequently overexpressed on tumor stem cells and the neovasculature of glioblastoma multiforme (GBM) and other solid tumors. The construct utilizes the IIIA4 murine monoclonal antibody—the precursor to the clinical-stage humanized antibody ifabotuzumab—linked to the microtubule-disrupting agent maytansine via a non-cleavable SMCC (succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate) linker. With a drug-to-antibody ratio (DAR) of approximately 2.81, the ADC is internalized upon binding to EphA3, leading to the release of the cytotoxic payload and subsequent cell death. Preclinical research has demonstrated its efficacy in orthotopic GBM xenograft models and patient-derived organoids, highlighting its potential to address tumor heterogeneity and chemo-resistance in aggressive brain cancers and hematopoietic malignancies.

Other names

EphA3-targeting antibody-drug conjugateEphA-3-targeting antibody-drug conjugateEphA 3-targeting antibody-drug conjugateIIIA4-maytansine conjugateIIIA-4-maytansine conjugateIIIA 4-maytansine conjugate